Showing results (21-30 of 122) with videos related to

Sort By:
Pageof 13
Clinical Lymphoma|March 30, 2005
Immunophenotypic and cytogenetic comparison of Waldenstrom's macroglobulinemia with splenic marginal zone lymphomaEnrique M Ocio, Jesus M Hernandez, Gema Mateo, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometryEnrique M Ocio, Daniel del Carpio, Álvaro Caballero, et al.
British Journal of Haematology|February 6, 2016
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO groupAlejandro Martín, Alba M Redondo, Iván Dlouhy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2013
Potent antimyeloma activity of a novel ERK5/CDK inhibitorStela Álvarez-Fernández, María Jesús Ortiz-Ruiz, Tracy Parrott, et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|July 7, 2023
Expert consensus on the integrated diagnosis of idiopathic multicentric Castleman diseaseSantiago Montes-Moreno, Fina Climent, Máximo Fraga, et al.
Blood Reviews|June 23, 2015
Treatment for patients with newly diagnosed multiple myeloma in 2015María-Victoria Mateos, Enrique M Ocio, Bruno Paiva, et al.
Haematologica|February 9, 2012
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotypeTeresa Paíno, Enrique M Ocio, Bruno Paiva, et al.
Haematologica|January 2, 2008
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotypeEnrique Colado, Stela Alvarez-Fernández, Patricia Maiso, et al.
European Journal of Haematology|June 26, 2025
European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future DirectionsThomas Lund, Cyrus Khandanpour, Sébastien Anguille, et al.
Leukemia|May 17, 2019
The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myelomaMarc S Raab, Sheeba K Thomas, Enrique M Ocio, et al.
Pageof 13